Pharmacodynamic effects during the transition between cangrelor and ticagrelor

JACC: Cardiovascular Interventions

Volumn 7, Issue 4, 2014, Pages 435-442

  Schneider, David J ^a   Agarwal, Zubin ^a   Seecheran, Naveen ^a   Keating, Friederike K ^a   Gogo, Prospero ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

antiplatelet; cangrelor; pharmacodynamics; ticagrelor; transition

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CANGRELOR; TICAGRELOR; VASODILATOR STIMULATED PHOSPHOPROTEIN; ACTIN BINDING PROTEIN; ADENOSINE; ADENOSINE PHOSPHATE; ANTITHROMBOCYTIC AGENT; CELL ADHESION MOLECULE; P2RY12 PROTEIN, HUMAN; PHOSPHOPROTEIN; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MALE; PHARMACODYNAMICS; PLATELET REACTIVITY; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; BLEEDING; CONTROLLED STUDY; DRUG EFFECT; FEMALE; ISCHEMIA; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING PARAMETERS; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG INTERACTION; DRUG SUBSTITUTION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; TIME; UNITED STATES;

ADENOSINE; ADENOSINE MONOPHOSPHATE; ADMINISTRATION, ORAL; AGED; BLOOD PLATELETS; CELL ADHESION MOLECULES; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG SUBSTITUTION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; TIME FACTORS; VERMONT;

EID: 84898788868     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2013.08.017     Document Type: Article

References (17)

1. D. Alexopoulos, I. Xanthopoulou, and G. Tsigkas et al. Intrinsic platelet reactivity and thrombus burden in patients with ST-elevation myocardial infarction Thromb Res 131 2013 333 337
2. G. Parodi, R. Marcucci, and R. Valenti et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI JAMA 306 2011 1215 1223
3. A. Nishiyama, O. Niikawa, H. Mohri, and M. Tsushima Timing of anti-platelet effect after oral aspirin administration in patients with sympathetic excitement Circ J 67 2003 697 700
4. G. Parodi, R. Valenti, and B. Bellandi et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study J Am Coll Cardiol 61 2013 1601 1606
5. D.L. Bhatt, G.W. Stone, K.W. Mahaffey for the CHAMPION PHOENIX Investigators Effect of platelet inhibition with cangrelor during PCI on ischemic events N Engl J Med 368 2013 1303 1313
6. D.J. Angiolillo, M.S. Firstenberg, M.J. Price for the BRIDGE Investigators Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial JAMA 307 2012 265 274
7. S.R. Steinhubl, J.J. Oh, J.H. Oestreich, S. Ferraris, R. Charnigo, and W.S. Akers Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect Thromb Res 121 2008 527 534
8. N.L. Dovlatova, J.A. Jakubowski, A. Sugidachi, and S. Heptinstall The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function J Thromb Haemost 6 2008 1153 1159
9. D.J. Angiolillo, D.J. Schneider, and D.L. Bhatt et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) trials J Thromb Thrombolysis 34 2012 44 55
10. D.L. Bhatt, A.M. Lincoff, C.M. Gibson CHAMPION PLATFORM Investigators Intravenous platelet blockade with cangrelor during PCI N Engl J Med 361 2009 2330 2341
11. R.A. Harrington, G.W. Stone, and S. McNulty et al. Platelet inhibition with cangrelor in patients undergoing PCI N Engl J Med 361 2009 2318 2329
12. R. Teng Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor Clin Pharmacokinet 51 2012 305 318
13. D.J. Schneider, and B.E. Sobel Streamlining the design of promising clinical trials: in-vitro testing of antithrombotic regimens and multiple agonists of platelet activation Coron Artery Dis 20 2009 175 178
14. L. Bonello, L. Camoin-Jau, and S. Arques et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in subjects with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol 51 2008 1404 1411
15. P.A. Gurbel, K.P. Bliden, and K. Butler et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in subjects with stable coronary artery disease: the ONSET/OFFSET study Circulation 120 2009 2577 2585
16. R.F. Storey, D.J. Angiolillo, and S.B. Patil et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in subjects with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy J Am Coll Cardiol 56 2010 1456 1462
17. A. Ravnefjord, J. Weilitz, B.M. Emanuelsson, and J.J. van Giezen Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model Thromb Res 130 2012 622 628